Should apixaban be held before removal of a port‑a‑cath?

Port-a-Cath Removal on Apixaban

You should hold apixaban for at least 24 hours (and ideally 48 hours) before port-a-cath removal, as this is a low-to-moderate bleeding risk procedure that requires minimal anticoagulation at the time of the intervention.

Bleeding Risk Classification

Port-a-cath removal is classified as a low-to-moderate bleeding risk procedure because:

• Surgical hemostasis can be readily achieved
• The bleeding site is easily accessible and compressible
• Major vascular injury is uncommon with proper technique

Recommended Interruption Strategy

Based on the most recent 2022 American College of Chest Physicians guidelines 1, the standardized approach for apixaban interruption is:

For Low-to-Moderate Bleed Risk Procedures:

• Hold apixaban for 1 day before and 1 day after the procedure (2 days total)
• This translates to: skip 2 doses before the procedure if taking twice daily dosing
• Last dose should be approximately 24 hours before the procedure 1

The FDA label supports this approach, stating that apixaban should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding 2.

Timing Details:

If taking apixaban twice daily (most common):

• Last dose should be the morning of the day before the procedure 3
• This provides approximately 24-36 hours of interruption

The French GIHP guidelines [@2-9@] similarly recommend interruption for low-risk procedures, though they suggest slightly longer windows for higher-risk scenarios.

Evidence Supporting This Approach

The PAUSE study 1, which included 1,257 apixaban-treated patients with atrial fibrillation undergoing elective procedures, demonstrated excellent safety with this standardized interruption:

• 30-day arterial thromboembolism rate: 0.16% (95% CI: 0-0.48%)
• 30-day major bleeding rate: 1.35% (95% CI: 0-2.0%)

A real-world prospective study 4 confirmed that apixaban discontinuation for at least 48 hours resulted in clinically insignificant anticoagulation levels (94% of patients achieved concentrations ≤30 ng/mL), with minimal bleeding complications.

Important Considerations

Renal Function:

• If creatinine clearance is 30-50 mL/min: Consider extending interruption to 48 hours (skip 4 doses) 3
• If creatinine clearance is <30 mL/min: Extend interruption further and consider measuring apixaban levels if available 1

Drug Interactions:

• If taking P-glycoprotein inhibitors or CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): Extend interruption time as these increase apixaban levels 3

Age Considerations:

• Patients ≥80 years old may have prolonged drug clearance; consider 48-hour interruption 3

Resumption After Procedure

Resume apixaban at least 6 hours after port removal once adequate hemostasis is confirmed 3, 2. The FDA label specifies that apixaban should be restarted "as soon as adequate hemostasis has been established" 2.

For twice-daily dosing:

• If procedure is in the morning: resume that evening
• If procedure is in the afternoon: resume the next morning 3

What NOT to Do

Do not use heparin bridging - this is explicitly not recommended for DOAC interruption and increases bleeding risk without reducing thrombotic events 3

Do not routinely measure apixaban levels - unnecessary when following recommended interruption periods unless urgent surgery or special circumstances (severe renal/hepatic impairment, drug interactions) 1, 3

Common Pitfall

The most common error is over-interrupting apixaban due to unfamiliarity with its pharmacokinetics. The half-life is approximately 12 hours 5, so 24 hours (2 half-lives) provides adequate clearance for low-risk procedures. Excessive interruption unnecessarily increases thrombotic risk, particularly in patients with atrial fibrillation or recent VTE.